Immatics N.V. Reports Promising Clinical Data for Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma

Immatics N.V. has provided updated data from its ongoing Phase 1b clinical trial evaluating Anzu-cel PRAME cell therapy in patients with metastatic uveal melanoma. The data cutoff was September 24, 2025, and included 16 patients who received a one-time infusion of Anzu-cel at the recommended Phase 2 dose. The results showed a confirmed objective response rate (cORR) of 67%, a disease control rate (DCR) of 88%, and a median duration of response (mDOR) of 11 months. The median progression-free survival (mPFS) was 8.5 months, and the median overall survival (mOS) was not reached at a median follow-up of 14.3 months. Anti-tumor activity was observed in liver and extrahepatic metastases, with a median shrinkage in liver target lesion size of 49.6%. The therapy demonstrated a favorable tolerability profile, with most adverse events being anticipated cytopenias associated with lymphodepletion. Based on these results, Immatics has initiated a Phase 2 cohort with approximately 30 uveal melanoma patients planned.